Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
- Actinium to Present on Tuesday, September 27, 2016 at 1:00 PM ET
- Management Will be Available for 1-on-1 Meetings with Conference Attendees
NEW YORK, Sept. 19, 2016 -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will be presenting at the Ladenburg Thalmann 2nd Annual Healthcare Conference being held on Tuesday, September 27, 2016 at the Sofitel Hotel in New York, New York. Details regarding Actinium’s presentation are below:
Event: Ladenburg Thalmann 2nd Annual Healthcare Conference
Location: Sofitel Hotel, New York, New York
Presentation Time: 1:00 PM ET
Room: Montmartre, Track 5
Management will be available for 1-on-1 meetings with conference attendees. To schedule a meeting with management please contact Steve O'Loughlin, Vice President, Finance and Corporate Development at [email protected].
Actinium’s presentation can be viewed live via webcast through the following link http://wsw.com/webcast/ladenburg2/atnm. The presentation will be archived and available for playback via the investor relations page of Actinium’s website http://ir.actiniumpharma.com/ir-calendar.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Contact: Steve O'Loughlin Vice President, Finance and Corporate Development Actinium Pharmaceuticals, Inc. [email protected]
